Dr. John L. Eckenrode, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 105
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
OK license 25942 -
Medical Oncology Physician
MI license 4301043836
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 105
- Services billed
- 2,524
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 57 | 44 |
| Established patient office or other outpatient visit, 30-39 minutes | 22 | 19 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 16 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Tulsa, OK | 22 |
| Revlimid (lenalidomide) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 9 payments worth $187 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $45.06 |
|---|---|
| Daiichi Sankyo Inc. | $41.95 |
| Aveo Pharmaceuticals, Inc. | $38.57 |
| Janssen Biotech, Inc. | $23.41 |
| Bayer HealthCare Pharmaceuticals Inc. | $20.54 |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.81 |
| Food and Beverage | $167 |
|---|---|
| Education | $20.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Aveo Pharmaceuticals, Inc. Feb 12, 2025 | Education FOTIVDA · Oncology · in-kind | $20.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.